Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation—A SWEDEHEART study

Fig 1. Flowchart of how the study cohort was defined.

Fig 2. The time from discharge from valve intervention to diagnosis of new-onset atrial fibrillation. The dotted line indicate the three months period after valve intervention.

Fig 3. The proportion of patients with atrial fibrillation and dispensation of oral anticoagulant treatment. The proportion of patients with history of atrial fibrillation and dispensation of oral anticoagulant treatment (A) at discharge from valve intervention. The proportion of patients with new-onset atrial fibrillation and dispensation of oral anticoagulant treatment (B) at start of the atrial fibrillation. Warfarin (blue line), NOAC (purple line) and no OAC (grey line).

Fig 4. The percent of time during follow up with dispensation of oral anticoagulant treatment. Warfarin (blue), NOAC (purple) and no OAC (grey) in patients with history of atrial fibrillation separated by the OAC dispensation at discharge from valve intervention, and in patients with new-onset atrial fibrillation separated by the OAC dispensation at diagnosis of atrial fibrillation.

Fig 5. The proportion of antithrombotic exposure in the history of atrial fibrillation (A) patients exposed to warfarin, warfarin + anti-platelet (AP), NOAC, NOAC + AP, anti-platelet, no treatment during the follow-up period after discharge from valve intervention. The figure describe patients included year 2010–2012, 2013–2014 and 2015–2017. The proportion of antithrombotic exposure in the new-onset atrial fibrillation (B) patients exposed to warfarin, warfarin + AP, NOAC, NOAC + AP, anti-platelet, no treatment during the follow-up period after AF diagnosis. The figure describes the patients included year 2010–2012, 2013–2014 and 2015–2017.